Literature DB >> 3489194

Descriptive epidemiology of motor neuron disease in Benghazi, Libya.

K Radhakrishnan, P P Ashok, R Sridharan, M E Mousa.   

Abstract

A total of 23 patients with motor neuron disease (MND), encompassing 17 cases of amyotrophic lateral sclerosis, 4 of progressive muscular atrophy and 2 of progressive bulbar palsy, was diagnosed in Benghazi, north-eastern Libya, between 1980 and 1985. The male to female ratio was 2.3:1. The average incidence of MND was 0.89/100,000 population/year (0.87 when age and sex-adjusted to the Libyan population). Eighteen patients were alive on the prevalence day, September 15, 1985, which provided a prevalence rate of 3.47/100,000 population (3.42 if adjusted). Age-specific incidence rates were highest in the 50- to 59-year-old age group, 8.14/100,000/year for men and 6.10/100,000/year for women. The median age at the time of diagnosis was 51 years, and the median duration for the 5 dead MND patients after the onset of the disease was 30 months. The median survival time for all MND cases combined was 42 months.

Entities:  

Mesh:

Year:  1986        PMID: 3489194     DOI: 10.1159/000110812

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  10 in total

1.  Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950.

Authors:  A M Chancellor; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-12       Impact factor: 10.154

Review 2.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.

Authors:  Benoît Marin; Giancarlo Logroscino; Farid Boumédiene; Anaïs Labrunie; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Pierre Marie Preux; Ettore Beghi
Journal:  Eur J Epidemiol       Date:  2015-10-12       Impact factor: 8.082

3.  Time-trend evolution and determinants of sex ratio in Amyotrophic Lateral Sclerosis: a dose-response meta-analysis.

Authors:  Andrea Fontana; Benoit Marin; Jaime Luna; Ettore Beghi; Giancarlo Logroscino; Farid Boumédiene; Pierre-Marie Preux; Philippe Couratier; Massimilano Copetti
Journal:  J Neurol       Date:  2021-02-25       Impact factor: 4.849

4.  The effect of autologous bone marrow mononuclear cell transplantation on the survival duration in Amyotrophic Lateral Sclerosis - a retrospective controlled study.

Authors:  Alok K Sharma; Hemangi M Sane; Amruta A Paranjape; Nandini Gokulchandran; Anjana Nagrajan; Myola D'sa; Prerna B Badhe
Journal:  Am J Stem Cells       Date:  2015-03-15

5.  A clinical, epidemiological and genetic study of hereditary motor neuropathies in Benghazi, Libya.

Authors:  K Radhakrishnan; A K Thacker; J C Maloo
Journal:  J Neurol       Date:  1988-09       Impact factor: 4.849

6.  Age-specific ALS incidence: a dose-response meta-analysis.

Authors:  Benoît Marin; Andrea Fontana; Simona Arcuti; Massimilano Copetti; Farid Boumédiene; Philippe Couratier; Ettore Beghi; Pierre Marie Preux; Giancarlo Logroscino
Journal:  Eur J Epidemiol       Date:  2018-04-23       Impact factor: 8.082

7.  Establishing a Libyan Medical Research Council is Urgently Needed.

Authors:  H Benamer
Journal:  Libyan J Med       Date:  2007-12-01       Impact factor: 1.657

Review 8.  Epidemiology of amyotrophic lateral sclerosis: an update of recent literature.

Authors:  Elisa Longinetti; Fang Fang
Journal:  Curr Opin Neurol       Date:  2019-10       Impact factor: 5.710

9.  Projected increase in amyotrophic lateral sclerosis from 2015 to 2040.

Authors:  Karissa C Arthur; Andrea Calvo; T Ryan Price; Joshua T Geiger; Adriano Chiò; Bryan J Traynor
Journal:  Nat Commun       Date:  2016-08-11       Impact factor: 14.919

Review 10.  Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis.

Authors:  Benoît Marin; Farid Boumédiene; Giancarlo Logroscino; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Massimilano Copetti; Pierre-Marie Preux; Ettore Beghi
Journal:  Int J Epidemiol       Date:  2017-02-01       Impact factor: 7.196

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.